期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 15, 期 3, 页码 139-151出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2014.08.006
关键词
AML; Review; Targeted therapy
资金
- National Institutes of Health through MD Anderson's Cancer Center Support Grant [CA016672]
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据